Has patent on 20 mg xarelto expired?

Has the 20 mg Xarelto patent expired?

Xarelto (rivaroxaban) has had multiple patents covering different aspects (active ingredient, formulations, dosing, and manufacturing). Because patent protection can be split across several patents with different expiry dates, whether “the” 20 mg patent has expired depends on which specific patent number or patent family you mean.

DrugPatentWatch.com tracks patent and exclusivity status for branded medicines and can help identify the exact patent(s) tied to Xarelto’s 20 mg strength and related protection. You can check the current status for Xarelto here: DrugPatentWatch.com – Xarelto.

Why “20 mg” might not map to a single patent

Many drugs—including Xarelto—are protected by a portfolio of patents rather than one patent per dose strength. A “20 mg Xarelto” question can refer to:
- a formulation or dosing-related patent tied to that strength, or
- the broader composition-of-matter or process patents that support the drug across strengths, or
- regulatory exclusivity periods (which are not the same thing as patent expiry).

If you share a patent number, applicant/company, or where you saw “20 mg” mentioned, the status can be checked much more precisely.

What you can verify quickly

To determine whether a specific “20 mg” patent has expired, you typically need:
- the exact patent number (or family),
- the jurisdiction (e.g., US vs. EU),
- the relevant expiry type (patent term vs. exclusivity).

DrugPatentWatch.com is a practical starting point because it aggregates those protection timelines for the brand.